GT Biopharma Valuation
| GTBP Stock | USD 2.06 0.05 2.37% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. GT Biopharma owns a latest Real Value of $4.27 per share. The recent price of the firm is $2.06. Our model calculates the value of GT Biopharma from inspecting the firm fundamentals such as EBITDA of 5.98 M, shares outstanding of 2.23 M, and Return On Asset of -0.61 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting GT Biopharma's valuation include:
Undervalued
Today
Please note that GT Biopharma's price fluctuation is very risky at this time. Calculation of the real value of GT Biopharma is based on 3 months time horizon. Increasing GT Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
GT Biopharma's intrinsic value may or may not be the same as its current market price of 2.06, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.06 | Real 4.27 | Target 11.0 | Hype 2.06 | Naive 1.93 |
The intrinsic value of GT Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence GT Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of GT Biopharma helps investors to forecast how GTBP stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GT Biopharma more accurately as focusing exclusively on GT Biopharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use GT Biopharma's intrinsic value based on its ongoing forecasts of GT Biopharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against GT Biopharma's closest peers.
GT Biopharma Cash |
|
GTBP Valuation Trend
GT Biopharma's real value is important for investors to make better decisions and a more accurate overall view of GT Biopharma's financial worth over time. Using both GT Biopharma's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
GT Biopharma Total Value Analysis
GT Biopharma is currently forecasted to have valuation of (5.17 M) with market capitalization of 6.23 M, debt of 58 K, and cash on hands of 23.73 M. The negative valuation of GT Biopharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the GT Biopharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(5.17 M) | 6.23 M | 58 K | 23.73 M |
GT Biopharma Asset Utilization
One of the ways to look at asset utilization of GTBP is to check how much profit was generated for every dollar of assets it reports. GT Biopharma owns a negative utilization of current and long term assets of -0.61 %, losing $0.006059 for each dollar of current and long term assets held by the firm. Discouraging asset utilization attests that the company is being less competent with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of GT Biopharma shows how wasteful it operates for each dollar spent on its current and long term assets.GT Biopharma Ownership Allocation
Over half of GT Biopharma's outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions.GT Biopharma Profitability Analysis
Net Loss for the year was (7.6 M) with profit before overhead, payroll, taxes, and interest of 0.About GT Biopharma Valuation
The stock valuation mechanism determines GT Biopharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of GT Biopharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of GT Biopharma. We calculate exposure to GT Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of GT Biopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -3.6 K | -3.4 K | |
| Pretax Profit Margin | -1.4 K | -1.3 K | |
| Operating Profit Margin | (380.22) | (361.21) | |
| Net Loss | -1.4 K | -1.3 K | |
| Gross Profit Margin | 1.06 | 1.12 |
GT Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as GT Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.3 M |
GT Biopharma Current Valuation Indicators
GT Biopharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final GT Biopharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as GT Biopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use GT Biopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes GT Biopharma's worth.Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.